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Accumulating evidence indicates that neutralizing antibodies play an important role in protection from
chronic hepatitis C virus (HCV) infection. Efforts to elicit such responses by immunization with intact
heterodimeric E1E2 envelope proteins have met with limited success. To determine whether antigenic sites,
which are not exposed by the combined E1E2 heterodimer structure, are capable of eliciting neutralizing
antibody responses, we expressed and purified each as separate recombinant proteins E1 and E2, fromwhich the
immunodominant hypervariable region (HVR-1) was deleted. Immunization of chimpanzees with either E1 or
E2 alone induced antigen-specific T-helper cytokines of similar magnitude. Unexpectedly, the capacity to
neutralize HCV was observed in E1 but not in animals immunized with E2 devoid of HVR-1. Furthermore, in
vivo only E1-vaccinated animals exposed to the heterologous HCV-1b inoculum cleared HCV infection.
The hepatitis C virus (HCV) envelope glycoproteins E1
and E2 are heterodimerically exposed on the surface of
the virion and play a crucial role in receptor binding,
viral fusion, and entry of HCV [1]. Combined, E1E2
heterodimers have long been considered and evaluated
as candidate HCV vaccine antigens, primarily, but not
exclusively, for the induction of neutralizing antibodies
[2]. Due to the different functions of the E1E2
heterodimer, it is safe to assume that it will undergo
conformational changes during the virus life cycle [3].
The E2 molecule in this complex is known to bind
specifically to cell-surface molecules such as CD81,
scavenger receptor class B type 1 (SR-B1), Claudin-1,
and others [1, 4]. However, in both E1 and E2, struc-
tural homologies to fusion mediating proteins of related
viral families have been described [5]. E2 also possesses
a major determinant of isolate-specific neutralizing
antibodies located near its N terminus called the
hypervariable region (HVR-1). However, due to its
immunodominance and the consequential selective
pressure on this region, it rapidly accumulates non-
synonymous mutations making it hypervariable, which
is an undesirable attribute for a candidate vaccine an-
tigen. In contrast, the role of E1 in HCV infection and
immunity is still unclear, yet several antibodies directed
against E1 were found to prevent cell entry [6, 7].
We rationalized that by removing the HVR-1 from
E2, and separating the 2 components of the hetero-
dimer, that novel structural features might be revealed,
creating new targets for the induction of broad neu-
tralizing antibodies. To test this hypothesis, chimpanzees
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were immunized with either recombinant E2 protein with the
HVR-1 deleted or the intact recombinant E1 protein alone. To
determine whether the vaccine-induced antibody responses were
sufficient to protect from persistent HCV infection, all animals
were exposed to a 1b inoculum, which has the propensity to
cause chronic infection. By 18 weeks, the 2 E1-immunized ani-
mals had cleared HCV infection, whereas RNA viremia persisted
in the 2 E2-immunized animals and the control animal. Vaccine-
induced protection from persistent HCV infection correlated
with E1-induced neutralizing antibodies, demonstrating a pre-
viously unrecognized role for E1 subunit in immunization.
MATERIALS AND METHODS
Animals
This study was critically reviewed and approved and undertaken
by the institute’s animal ethical committee and performed in
accordance with Dutch law and international guidelines for the
use of animals in research (BPRC IACUC ID 253) in consulta-
tion and prior to amended Dutch legislation. Five mature,
captive bred chimpanzees (Pan troglodytes verus), naive for
retroviruses and hepatitis viruses, were socially housed and
monitored multiple times per day by experienced veterinary
staff (BPRC, Rijswijk, The Netherlands).
Throughout the study, animals were checked twice daily for
general behavior, appetite, and stool consistency. Body weight,
rectal temperature, hematology, and clinical chemistry were
assessed during each sedation for immunization, blood collec-
tion, or liver biopsy. Serum and peripheral blood mononuclear
cells (PBMCs) were isolated from heparinized blood samples
collected using aseptic techniques as described elsewhere [8].
HCV Immunogens and Assay Antigens
Recombinant HCV envelope proteins E1s (aa192–aa326) and
E2DHVR-1 (E2 aa412–aa715 with deletion of HVR-1 aa384–
aa411) were used for immunizations and in the cellular assays.
Both proteins were derived from the European HCV 1b BE11
strain and were expressed by recombinant vaccinia virus
transfected Vero cells; purity of all proteins was estimated to
be .95% by SDS-PAGE [9]. For immunization, E1 and E2
proteins were formulated with Alum (Alhydrogel, Superfos
Biosector), 1.3% Al(OH)3 in phosphate-buffered solution,
and diluted with physiological saline to a final protein concen-
tration of 50 lg/mL and 0.13% Al(OH)3. Although both
the vaccine proteins as well as the challenge virus were derived
from genotype HCV 1b, the challenge was considered heterol-
ogous because in E1 7% and in E2 11% of the amino acid
residues were different between the vaccine and challenge
sequence.
To analyze virus-induced immune responses after challenge,
HCV NS3 (NS3 1071–1084 and 1181–1465), an Eschericia coli
fusion protein based on a HCV 1b isolate (BE8309), was used.
Experimental Design, Immunizations, and HCV Exposure
Chimpanzee E1-Ma and E1-Yo were immunized with 50 lg of
E1, whereas E2-Jo and E2-Ka received 50 lg of E2 recombi-
nant protein. One animal, Ctrl-Hu, served as a challenge
control and did not receive any HCV immunogen or adjuvant
before challenge.
Animals were given intramuscular immunizations in the bi-
ceps at weeks 0, 3, 6, 9, 12, and 15 at a dose of 50 lg of protein
per mL diluted Alum (Figure 1). At week 18, the animals were
intravenously exposed to 100 CID of an in vitro-titrated HCV 1b
inoculum J4.91’01, diluted in saline.
Humoral Responses
Vaccine-specific antibody titers were determined by limiting
dilution ELISA [8] or INNO-LIA HCV (Innogenetics).
HCV-neutralizing capacity of longitudinal serum samples
was determined before and during the immunization period
at weeks 7 and 17 and at week 107, which is 89 weeks after
infection. The assay was performed as described elsewhere
[10–12] with HCVpp-expressing E1 and E2 envelope glyco-
proteins of the isolates CG (J) (AF333324) and UKN1B 12.6
(AY734975)
Virus Quantification
Quantification of HCV RNA in serum was monitored using
Amplicor (Roche Diagnostics) [13].
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Figure 1. Humoral responses. A , Vaccine-specific antibody titers
over time, ie, E1-specific antibodies were measured in E1-Ma and E1-Yo,
and E2-specific antibodies in serum from E2-Ka and E2-Jo. Time points of
immunizations are indicated by gray arrows under the X-axis, and the
time point of challenge is indicated by a black arrow. The shaded area
represents the post-challenge follow-up period. B , Evaluation of cross-
reactivity. Serum samples collected at weeks 0, 13, 14, 15, and
16 (separate bars) were tested for binding to E1 and E2 with standard
ELISA.
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Cellular Immune Responses
The number of HCV-specific PBMCs was determined by lym-
phoproliferation and ELISPOT assay at regular time points
during the immunization period and after experimental HCV
exposure as described elsewhere [8].
Analysis of HCV E1 and E2 Sequence Diversity
Viral RNA was isolated at weeks 1, 3, 6, 12, 31, 36, and 41 weeks
after challenge for as long as the virus was detectable in serum,
making use of the QIAamp Viral RNA Mini Spin protocol
(QIAGEN). DNA synthesis and outer polymerase chain reaction
(PCR) was performed in one step using the QIAGEN OneStep
RT-PCR kit, followed by a conventional nested PCR. The
following primer sets were used to sequence E1; outer primer set
HCPr638 (5#CTG TCY TGY TTG ACC RTC CCA GC3# nt 544–
566 when aligned–H77) and HCPr639 (5#CCC GTC AAC GCC
GGC RAA GAG TAR C3# nt 1149–1125) inner primer set
HCPr640 (5#GTY TGA CCA YCC CAG CTT CCG CT3# nt 551–
573) and HCPr641 (5#TCA ACG CCG GCR AAR AGT ARC
RYC AC3# nt 1145–1120). To completely cover the E2 region, the
following 3 primer sets were used. Fragment I: outer primer
HCPr642 (5#TGG CGC TAC TCT TTG CCG GCG TTG A3# nt
1121–1145) and HCPr643 (5#AGG CAC CTA GGT GTC AAC
CA3# nt 1844–1825); inner PCR HCPr644 (5#CGG CGT TGA
CGG GGC GAC CTA3# nt 1137–1157) and HCPr645 (5#CCC
GAG CCA CAT TTT GTG TA3# nt 1820–1801). Fragment II:
outer HCPr691 (5#GTG TGY GGY CCA GTG TAY TG3# nt
1510–1529) and HCPr692 (5#CCA CTC YGT YGT RGA CAG
YA3# nt 2037–2018); inner HCPr693 (5#GAY GTG RTG CTY
CTY AAC AA3# nt 1609–1628) and HCPr694 (5#TCC TCC AAG
TYR CAR CGC TC3# nt 1988–1969). Fragment III: outer
HCPr646 (5#TGA TCT GCC CCA CGG ACT GC3# nt 1757–
1776) and HCPr647 (5#TCCCGG TCCAAGGCG TAAGC3# nt
2459–2440); inner primers HCPr648 (5#ACG GAC TGC TTC
CGG AAG CA3# nt 1768–1787) and HCPr649 (5#GGC GTA
AGC TCG TGG TGG TA3# nt 2448–2429).
RESULTS
Vaccine-Specific Antibody Responses
The induction of vaccine-specific antibodies in serum was de-
termined by ELISA. As shown in Figure 1, all 4 vaccinees de-
veloped envelope-specific antibodies with similar magnitude
and kinetics, increasing following each immunization and
peaking 14–17 weeks following the first immunization. After
experimental HCV exposure at week 18, HCV-specific antibody
responses gradually declined, yet persisted at low levels until the
end of the study. Similar declines have been noted previously by
us and others as a frequent sequelae of HCV infection in
chimpanzees. Antibody formation directly after experimental
infection is low and often falling below the detection limits
of standard ELISA assays [14, 15]. In the control animal
HCV-specific antibodies were only observed after challenge
(data not shown).
Induction of HCV-Specific T-Cell Responses by Immunization
Induction of cellular immune responses against the vaccine
proteins (E1 or E2), as well as an HCV protein not included in
the vaccine (NS3), were assessed by lymphocyte proliferation
and ELISPOT analysis. As shown in Figure 2, both E1-
immunized animals and the 2 E2-immunized animals developed
vaccine-induced interleukin 4 (IL-4) secreting cells (140 IL-4
sfu/106 PBMCs in E1-Ma, 44 IL-4 sfu/106 in E1-Yo, 217 IL-4
sfu/106 in E2-Ka, and 106 IL-4 sfu/106 in E2-Jo). Instead, the
number of vaccine-induced interferon c (IFN-c) secreting cells
was much lower in all 4 animals (,10 sfu/106 PBMCs in each
animal). These data implied a Th2-dominant immune response,
which correlated with high vaccine-induced antibody levels in
serum at the time point of challenge. As expected, only weak
cellular immune responses were observed against the non-
vaccine viral protein NS3 following HCV exposure in all 5 an-
imals. Expectedly, NS3-specific responses were IFN-c biased,
whereas the envelope-specific responses preserved their Th2-
like characteristics. T-cell responses were further substantiated
by lymphoproliferation and IL-2 ELISPOT (Supplementary
Figure 1). Although E2-Jo was only immunized with recombi-
nant E2 protein and not with E1, in vitro stimulation of PBMCs
with E1 also induced cytokine production. This cross-reaction
between the 2 envelope proteins was also observed in the hu-
moral response (Figure 1B). Serum samples collected at weeks
0, 13, 14, 15, and 16 from E2-Jo were found to have some
reactivity against E1, which was low compared with the E2
binding. Neither E1- nor E2-specific T-cell responses were
observed prior to challenge in Ctrl-Hu.
Neutralizing Capacity of Vaccine-Induced Antibodies
To determine whether the antibodies induced by the vaccine
proteins E1 or E2 were functional in neutralizing HCV, pseu-
doparticle assays (HCVpp) were performed on serum obtained
before and 7, 17, and 107 weeks after initial immunization. The
HCVpp were pseudotyped with E1E2 glycoproteins derived
from strain UKN1B 12.6, which has a closely related amino acid
sequence to the vaccine strain, or CG (J), an isolate most similar
to the challenge inoculum [16]. As a control, the glycoprotein
from RD114, the cat endogenous virus, was used. Figure 3 dis-
plays the percentage of target cells infected by HCVpp, and the
inhibition of infection by serum from vaccinees obtained at
different time points. Comparison of the percentage of infection
between the immunized animals and the control animal Ctrl-Hu
showed more efficient inhibition by sera obtained from the
E1-immunized animals than by sera from the E2-immunized
animals. At week 7, both of the E1-immunized animals de-
veloped antibodies that strongly inhibited CG (J) HCVpp
infection (P , .01; 2-way ANOVA), whereas no inhibition
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was observed by sera from the 2 E2-immunized animals. This
CG (J) neutralization was also observed, but at a somewhat re-
duced level, at week 17 during the pause between immunization
and viral exposure. In both E1-immunized animals, significant
neutralization (P , .01) was also observed against HCVpp
exposing the UKN1B 12.6 envelope both at weeks 7 and 17.
Figure 2. HCV-specific IL-4 and IFN-c responses. Magnitude over time of IL-4 and IFN-c cytokine responses of individual animals were measured
against recombinant proteins HCV E1 (black bars), E2 (gray bars), and NS3 (white bars). Responses are shown for the 2 E1 protein-immunized animals
E1-Ma and E1-Yo, the 2 E2 protein-immunized animals E2-Ka and E2-Jo, and the naive control animal Ctrl-Hu. Immunizations were given at weeks 0, 3, 6,
9, 12, and 15, followed by HCV exposure at week 18. The shaded area represents the postchallenge follow-up period. Shown are the numbers of antigen-
specific spot-forming cells per million PBMCs minus the background (mean of triplicate medium controls).
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As expected, persistent HCV infection induced neutralizing
antibodies inhibiting HCVpp infection with both CG (J), as
well as UKN1B 12.6 isolates (week 107; Figure 3). Vaccine-
induced levels of neutralization declined in the absence of HCV
in E1-Ma and E1-Yo.
Neutralizing Antibody Titers Correlate With Clearance of
Infection
Three weeks after the final protein immunization, efficacy
against viral challenge was evaluated by intravenous exposure to
100 CID HCV 1b J4.91’01. All 4 vaccinees and the naive control
animal became acutely infected. A peak virus load between 1 and
5 3 105 IU mL21 was reached 1–6 weeks after challenge in all
animals except E2-Ka, where the peak viremia was 1 log lower
(Figure 4A). Subsequently, the virus load decreased to levels
between 103 and 104 IU mL21 in the control and the 2 E2-
immunized animals. Instead, in the 2 E1-immunized animals
virus became undetectable in serum and liver biopsies by
quantitative PCR 18 weeks after challenge. Furthermore, liver
enzyme levels ALT and cGT returned to prechallenge values
in these 2 animals (Figures 4B and 4C). In contrast to the
E1-immunized animals, all others remained persistently infected
and retained slightly elevated liver cGT (Figure 4C) (P 5 .039,
2-tailed Student t test).
No Evidence for Selective Immune Pressure Directed Against
Envelope Regions
To rule out that development of chronic infection in the E2-
vaccinated animals was either due to an ineffective E2-induced
vaccine response, or due to viral evolution and vaccine escape,
we performed longitudinal sequence analysis of the E1 and E2
regions of the predominant viral variants in plasma. Further-
more, we compared these sequences to the challenge inoculum
J4.91’01, as well as a parental virus isolate from which it was
derived HC-J4/91 (D10750) [17]. As shown in Figure 5, all the
nonsynonymous mutations relative to the inoculum aligned. In
the acute phase, only 1 amino acid residue change was observed
in the E1 region (G232A or G232D) and 3 in the E2 region
(F438L, A466V, and V496I). These changes seem to be unrelated
to the vaccination strategy, because they are observed in all ani-
mals irrespective of the antigen with which they were immunized.
In the chronic phase of infection in the animals not im-
munized with E1, 3 de novo mutations occurred in putative
E1 epitopes (V219M, T256A, and V301M) and 2 in E2
(H434Q and T444A). Surprisingly, all residues that became
established during the acute phase reverted to the residue
found in the original inoculum. Interestingly, with the ex-
ception of position 301 in the E1 region (valine in E2-Jo and
methionine in the other animals), the dominant viral variants
(in both E1 an E2 regions) that emerged at the end of the
study were found to be identical in the 3 animals that became
persistently infected.
Figure 3. Neutralizing antibodies. Serum samples collected before
immunization and at weeks 7, 17, and 107 were tested for the inhibition
of infection of Huh-7 target cells by HCVpp. Serum was tested against
CG (J) and UKN1B 12.6 HCV isolate envelopes, whereas RD114, a cat
endogenous virus-derived envelope, served as a control. Results are
expressed as percentage of infected cells. Plotted in the graphs are the
results of 2 independent assays, both performed in duplicate.
*Reduction of percentage of infected cells compared with the control
animal (P , .01).
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DISCUSSION
The partial characterization of the immune correlates of clear-
ance of HCV infection and the identification of the targeted viral
antigens facilitated the rational development of a vaccine for the
prevention of chronic HCV infection [8, 18, 19]. HCV vaccine
studies directed at the induction of virus neutralizing antibodies
have focused on the use of either the E1E2 heterodimer or the E2
protein alone [2, 15, 20, 21]. However, 2 lines of evidence have
suggested a role for E1. First, broadly neutralizing human
monoclonal antibodies to the E1 glycoprotein have been
identified [6, 7]. Second, functional analysis has identified sev-
eral membrane active regions in E1 (as well as E2) involved in
virus-cell membrane fusion [5].
In this study, we tested the hypothesis that the independent
use of HCV E1 subunit as a vaccine immunogen would be
capable of inducing neutralizing antibodies and facilitating
protection from HCV infection. Interestingly, although immu-
nization with E1 was successful in inducing neutralizing anti-
bodies, these did not have a direct blunting of the acute viral
peak after a relatively high dose, intravenous HCV exposure.
Ultimately, E1-neutralizing antibodies, together with recruited
Th responses, appear to have facilitated HCV 1b clearance.
However, additional mechanisms such as antibody-dependent
cellular cytotoxicity, recruited innate responses in the liver, or
late induction of cytotoxic T lymphocyte activity may have
contributed to clearance.
Although antibodies were also present in the serum of the E2-
immunized animals, these antibodies lacked the ability to neu-
tralize HCV, and the virus persisted in these animals. It could be
speculated that the E2 protein devoid of its HVR-1 was misfolded
and incapable of inducing NAbs. However, comparison of E2
proteins with and without HVR-1 for reactivity with a range of
patient sera showed no clear differences, suggesting that the
conformational structure of the E2 protein lacking the HVR-1 as
used in this study was antigenically intact (data not shown).
Although the immune responses observed in the E1-
immunized animals were restricted to the vaccine component,
chimpanzee E2-Jo not only responded to E2 but also to E1 in
both cellular as well as humoral immune assays. Although this
observation is somewhat unexpected, it must be noted that
shared immunoreactivity between the 2 envelope glycoproteins
was reported elsewhere [22] and may be elicited in animals that
carry the appropriate major histocompatibility complex makeup.
The majority of the HCV vaccine efficacy studies in chim-
panzees were done before the development of suitable HCV
neutralization assays; therefore, only limited data have been
available on the correlation of HCV neutralization and vaccine
efficacy. Furthermore, in the majority of HCV protein vaccine
efficacy studies to date, E1 and E2 were administered as heter-
odimer [21] and as the HCVpp also express E1 and E2, it is
impossible to determine the role of the separate envelope com-
ponents. To or knowledge, this is the first study to demonstrate
a direct correlation with vaccine-induced E1-neutralizing anti-
bodies and early clearance of HCV infection. Earlier studies
have focused on E2 as the lead vaccine target given the ob-
servations of E2-binding inhibition assays and the character-
ization of several E2-specific virus-neutralizing mAb [23, 24].
The E2 antigen used in this study was devoid of the HVR-1, and
therefore the outcome does not allow direct comparison with
earlier protein vaccine efficacy studies. Our efforts to focus the
immune response to the more conserved regions of E2 failed
because the antibodies generated with this strategy did not inhibit
infection with HCVpp. The lack of the HVR-1 may possibly have
reduced binding to one of the SR-B1 regions [11, 25]. Because
SR-B1 also mediates HCV uptake and cross-presentation by
dendritic cells in humans [26], this may have resulted in sub-
optimal antigen presentation and the formation of lower affinity
Figure 4. Viral load and liver enzymes. Shown are (A ) the plasma viral
load (copies mL21), (B ) ALT levels (IU mL21), and (C ) cGT (U mL21) in
individual animals observed over time.
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antibodies with reduced neutralizing capacity, despite induction
of high T-cell and binding antibody responses.
After immunization, all vaccinees developed an antigen-
specific Th-2–dominant immune response directed toward the
vaccine components as shown by increased lymphoprolifera-
tion, the high number of HCV-specific IL-4–secreting cells, and
by the formation of HCV-specific antibodies before challenge.
The degree of protection observed against this heterologous 1b
variant is different from the complete protection obtained with
E1E2 heterodimers against HCV-1a challenge of chimpanzees
[15]. However, our data concur with the outcome of reexposure
to HCV in humans and chimpanzees, where viral clearance is
observed much later, after the acute phase [2].
Although vaccine-mediated formation of viral escape variants
is of great concern, this activity was not observed in this study.
This proof of principle study reveals the previously un-
recognized importance of E1 alone as a candidate HCV vaccine
antigen. Moreover, these findings suggest that further insights
into the structure-function relationship of the E1E2 heterodimer
are required. Improved understanding of the dynamics and
structural changes on receptor binding and membrane fusion
may reveal conserved domains that could be exploited as neu-
tralizing antibody targets for immunization.
Supplementary Data
Supplementary Data are available at The Journal of Infectious
Diseases online.
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